Tudorza Pressair Powder, Metered
NDC Package 70515-002-01
Package Information
Tudorza Pressair (aclidinium bromide) powders is aclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). This formulation utilizes a powder, metered delivery system. Marketed by Covis Pharma Us, Inc, this product is identified by NDC 70515-002 and is authorized under FDA application NDA202450.
Identification & Billing
- RxCUI: 1303102 - aclidinium bromide 400 MCG/INHAL Dry Powder Inhaler, 60 ACTUAT
- RxCUI: 1303102 - 60 ACTUAT aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler
- RxCUI: 1303102 - 60 ACTUAT aclidinium bromide 400 MCG/ACTUAT Dry Powder Inhaler
- RxCUI: 1303102 - aclidinium bromide 0.4 MG/ACTUAT Dry Powder Inhaler, 60 ACTUAT
- RxCUI: 1303107 - Tudorza Pressair 400 MCG/INHAL Dry Powder Inhaler, 60 ACTUAT
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70515 - Covis Pharma Us, Inc
- 70515-002 - Tudorza Pressair
- 70515-002-01 - 1 POUCH in 1 CARTON / 1 INHALER in 1 POUCH / 60 POWDER, METERED in 1 INHALER
- 70515-002 - Tudorza Pressair
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70515-002). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70515-002-01 identifies a specific commercial package of 1 pouch in 1 carton / 1 inhaler in 1 pouch / 60 powder, metered in 1 inhaler of Tudorza Pressair, a human prescription drug labeled by Covis Pharma Us, Inc. This powder, metered is formulated for respiratory (inhalation) use and contains aclidinium bromide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Covis Pharma Us, Inc on July 01, 2015. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Aclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Aclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.
How is this Covis Pharma Us, Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70515000201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.